TMO.US Weekly Report · 2026-W31
This week Thermo Fisher Scientific experienced two distinct phases: early weakness from broader market pullback down to a weekly low, followed by a rebound triggered by Q2 earnings. The report beat expectations (EPS 4.68 +9.38% YoY, revenue $11.99B +10.49%), with management raising full-year guidance, driving a weekly gain of 1%. Notably, this rally occurred amid full-spectrum capital outflows, suggesting the advance was driven by technical short-covering rather than institutional accumulation.
Price Action
Early in the week the stock touched 556.01 before rebounding to close at 574.30, a weekly gain of 1.06%. The intra-week range of 5.7% was anchored by July 28 as the inflection point — the session hit 588.56 (weekly high) on Q2 earnings release and guidance raise.
Daily average volume of 2.38 million shares showed modest expansion relative to the 60-day median, though the turnover rate of 0.57% indicates moderate trading intensity. July 28-29 saw elevated volumes (3.03M and 2.55M shares respectively), declining thereafter, reflecting short-term profit-taking pressure. The weekly candle pattern formed a “V” reversal; however, the week closed below the intra-week high, suggesting momentum began to fade by Friday.
Valuation and Earnings
Current P/E of 30.77 sits at the 18.75th percentile over the past three years — meaning valuations were more expensive about 81% of the time historically. This represents a lower quartile position. P/B of 4.05 is reasonable by comparison.
Q2 delivered EPS of 4.68, up 9.38% YoY; revenue of $11.99B, up 10.49% YoY; net margin of 14.47%, down slightly QoQ but still robust. Relative to Q1, EPS expanded 5.6% sequentially and revenue 8.9%, showing sequential acceleration.
For full-year 2026, consensus EPS estimate stands at 26.25; through Q1+Q2 the company has realized 9.11, representing 35% completion—on par with a mid-year pace. The median analyst target price is 627.62, implying 8.8% upside to current levels.
Capital Flows and Institutional Sentiment
All capital segments flowed outward this week — large cap net outflow 419, mid-cap 1,071, and small-cap 1,141 (in longbridge units). All three tiers negative signifies both institutional and retail participants were reducing exposure, creating a stark disconnect with price appreciation. This typically indicates the rally was driven by short-covering or forced rebalancing rather than fresh buying.
Rating distribution: 19 Strong Buy, 3 Buy, 6 Hold, 2 No Rating, with 73% in buy categories. Ratings typically lag market signals by 1-2 weeks and should not be treated as real-time, but the overall bias suggests institutional confidence in the company’s medium-term trajectory remains intact.
Weekly Newsline
- THERMO FISHER SCIENTIFIC INC. 2026: Revenue $11.99B, EPS $4.68— 10-Q Summary
- U.S. stock market midday update: Thermo Fisher Scientific up 9.24%, earnings report exceeds expectations + AI new product launch
- Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 9.89% on Jul 23: A Full Analysis
- Thermo Fisher Rated Buy on Broad-Based Recovery, Conservative Guidance, and Attractive Valuation Versus Peers
- Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026
- Thermo Fisher surges 10% on raised FY2026 guidance and dividend
- Thermo Fisher President, COO Gianluca Pettiti sells 400 shares for $226,000
- One of the market’s ‘most durable growth’ sectors has been passed over for AI, says JPMorgan
- Liontrust Investment Partners LLP Sells 104,298 Shares of Thermo Fisher Scientific Inc. $TMO
- Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $634.92, Implies 13% Upside
The newsflow this week centered on Q2 earnings and guidance. The July 23 report beat consensus, triggering a 9.89% single-day jump. Management raised full-year guidance in tandem, boosting confidence in H2 execution. On the product front, the company’s ADLM 2026 presentation of new diagnostic and lab solutions was positioned as critical to long-term sector growth. On the institutional side, some holders (Liontrust) trimmed modestly while overall ratings remain Buy-heavy, with multiple analysts raising price targets. Notably, insider selling (president sold 400 shares) alongside strong institutional buy ratings creates a minor divergence, suggesting short-term profit-taking coexists with medium-term optimism.
Summary
Valuation, earnings, and institutional sentiment form a consistent bullish triad — historically depressed multiples, beats to estimates, and 73% buy ratings. Yet this week’s full-spectrum capital outflow conflicting with price appreciation reveals the rally’s true driver: primarily technical short-covering rather than fresh institutional deployment. The key watch ahead is whether post-Friday capital flows reverse, and whether profit-taking at higher levels is absorbed by forward guidance. Current valuation is attractive on relative metrics, but the absence of aligned capital inflows hints that further gains will require additional catalysts to confirm momentum sustainability.